/ The Lancet
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; for the BASKET-SMALL 2 Investigators
Lancet. 2020 Oct 19:S0140-6736(20)32173-5.
doi: 10.1016/S0140-6736(20)32173-5. Epub ahead of print. PMID: 33091360.
Pathologically obstructed, fine blood vessels can be opened just as easily with a balloon as with a stent. This was demonstrated by the team around DKF research group leader Prof. Raban Jeger (Cardiology/USB) in the "Basket-SMALL 2" study. In the long run, both methods also yield equally good results for patients. Vascular treatment with balloon has the advantage that no implant has to be inserted into the blood vessel.